MedTrace Logo

Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol

NCT01974167 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2014-08-06

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of eldecalcitol monotherapy compared with alfacalcidol monotherapy in patients with glucocorticoid-induced osteoporosis, using a randomized, open-label, parallel-group, comparative design.

Conditions

Interventions

DRUG

Eldecalcitol

Eldecalcitol 0.75 microgram once daily orally

DRUG

Alfacalcidol

Alfacalcidol 1 microgram once daily orally

Sponsors & Collaborators

  • e-GLORIA trial Protocol Review Committee

    lead INDUSTRY

Principal Investigators

  • Toshio Matsumoto · University of Tokushima

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2018-02-28

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01974167 on ClinicalTrials.gov